4.7 Article

Mapping of a novel susceptibility locus suggests a role for MC3R and CTSZ in human tuberculosis

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1164/rccm.200710-1554OC

Keywords

tuberculosis; host genetics; MC3R; Africa

Funding

  1. Medical Research Council [G0000690] Funding Source: Medline
  2. Wellcome Trust [079828, IC18CT980375] Funding Source: Medline

Ask authors/readers for more resources

Rationale: Tuberculosis remains a major cause of morbidity and mortality in the developing world. A better understanding of the mechanisms of disease protection could allow novel strategies to disease management and control. Objectives: To identify human genomic loci with evidence of linkage to tuberculosis susceptibility and, within these loci, to identify individual genes influencing tuberculosis susceptibility. Methods: Affected sibling pair analysis in South African and Malawian populations. Independent case-control study in West Africa. Measurements and Main Results: Two novel putative loci for tuberculosis susceptibility are identified: chromosome 6p21-q23 and chromosome 20q 13.31-33-the latter with the strongest evidence for any locus reported to date in human tuberculosis (single point LOD score of 3.1, P = 10(-4), with a maximum likelihood score [MLS] of 2.8). An independent, multistage genetic association study in West African populations mapped this latter region in detail, finding evidence that variation in the melanocortin 3 receptor (MC3R) and cathepsin Z (CTSZ) genes play a role in the pathogenesis of tuberculosis. Conclusions: These results demonstrate how a genomewide approach to the complex phenotype of human tuberculosis can identify novel targets for further research.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Chemistry, Multidisciplinary

TB Elimination Requires Discovery and Development of Transformational Agents

Christian Lienhardt, Mario C. Raviglione

APPLIED SCIENCES-BASEL (2020)

Review Biochemistry & Molecular Biology

The molecular pathology of pathogenic mitochondrial tRNA variants

Uwe Richter, Robert McFarland, Robert W. Taylor, Sarah J. Pickett

Summary: Mitochondrial diseases are a group of clinically and genetically heterogeneous disorders caused by pathogenic variants in either the nuclear or mitochondrial genome. This review focuses on the most common pathogenic mt-tRNA variants, exploring their clinical manifestations, molecular pathologies, and potential molecular mechanisms of disease. Additionally, the role of mitochondrial-nuclear crosstalk in the manifestation of mt-tRNA-associated disease and the potential for developing treatment options are discussed.

FEBS LETTERS (2021)

Article Neurosciences

Imaging mass cytometry reveals generalised deficiency in OXPHOS complexes in Parkinson's disease

Chun Chen, David McDonald, Alasdair Blain, Ashwin Sachdeva, Laura Bone, Anna L. M. Smith, Charlotte Warren, Sarah J. Pickett, Gavin Hudson, Andrew Filby, Amy E. Vincent, Doug M. Turnbull, Amy K. Reeve

Summary: This study utilized imaging mass cytometry to analyze the proteomic profiles of mitochondrial complexes in neurons from Parkinson's disease patients. The results revealed a widespread decrease in expression of all mitochondrial complexes in Parkinson's neurons, with a more severe decrease in mitochondrial disease neurons. Furthermore, the combination of affected complexes varied between the two groups, suggesting a potential compensatory increase in mitochondrial mass as a response to dysfunction.

NPJ PARKINSONS DISEASE (2021)

Article Critical Care Medicine

Evidence-based Definition for Extensively Drug-Resistant Tuberculosis

Maroussia Roelens, Giovanni Battista Migliori, Liudmila Rozanova, Janne Estill, Jonathon R. Campbell, J. Peter Cegielski, Simon Tiberi, Domingo Palmero, Greg J. Fox, Lorenzo Guglielmetti, Giovanni Sotgiu, James C. M. Brust, Didi Bang, Christian Lienhardt, Christoph Lange, Dick Menzies, Olivia Keiser, Mario Raviglione

Summary: The study supports a new definition of XDR-TB as MDR-TB with additional resistance to FQ plus bedaquiline and/or linezolid, which helps assess the adequacy of this definition for surveillance and treatment choice.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)

Review Medicine, Research & Experimental

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials

N. K. Hills, J. Lyimo, P. Nahid, R. M. Savic, C. Lienhardt, P. P. J. Phillips

Summary: This study reviewed 31 clinical trials and found heterogeneous outcome definitions, highlighting the need to establish clearer specification and move towards universal standardization of outcomes across pulmonary TB trials. The ICH E9 (R1) addendum provides guidelines for achieving this goal.

TRIALS (2021)

Review Microbiology

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

Mark S. Butler, Valeria Gigante, Hatim Sati, Sarah Paulin, Laila Al-Sulaiman, John H. Rex, Prabhavathi Fernandes, Cesar A. Arias, Mical Paul, Guy E. Thwaites, Lloyd Czaplewski, Richard A. Alm, Christian Lienhardt, Melvin Spigelman, Lynn L. Silver, Norio Ohmagari, Roman Kozlov, Stephan Harbarth, Peter Beyer

Summary: There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. The World Health Organization has identified antibiotic-resistant priority pathogens and critically analyzed the antibacterial clinical pipeline. While new antibacterial drugs are being developed, there is still a lack of clinically differentiated agents.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Editorial Material Immunology

Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case

Sonali Kochhar, Draurio Barreira, Pauline Beattie, Marco Cavaleri, Alejandro Cravioto, Mike W. Frick, Ann M. Ginsberg, Ian Hudson, David C. Kaslow, Sherry Kurtz, Christian Lienhardt, Shabir A. Madhi, Christopher Morgan, Yalda Momeni, Deepali Patel, Helen Rees, Taryn Rogalski-Salter, Alexander Schmidt, Boitumelo Semete-Makokotlela, Gerald Voss, Richard G. White, Matteo Zignol, Birgitte Giersing

Summary: Currently, there is a lack of formal mechanisms or systematic approaches to provide vaccine developers with anticipated evidence to support global policy recommendations. To address this issue, the World Health Organization (WHO) is evaluating a new strategic alignment tool called Evidence Considerations for Vaccine Policy (ECVP). The aim of ECVPs is to bridge the gap in evidence needs and reduce the risk of delays between vaccine recommendation and use.

VACCINE (2022)

Letter Microbiology

Reply to Kaye and Belley, Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too! REPLY

Mark S. Butler, Valeria Gigante, Hatim Sati, Sarah Paulin, Laila Al-Sulaiman, John H. Rex, Prabhavathi Fernandes, Cesar A. Arias, Mical Paul, Guy E. Thwaites, Lloyd Czaplewski, Richard A. Alm, Christian Lienhardt, Melvin Spigelman, Lynn L. Silver, Norio Ohmagari, Roman Kozlov, Stephan Harbarth, Peter Beyer

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Article Medicine, General & Internal

Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis

Juan F. Vesga, Christian Lienhardt, Placide Nsengiyumva, Jonathon R. Campbell, Olivia Oxlade, Saskia den Boon, Dennis Falzon, Kevin Schwartzman, Gavin Churchyard, Nimalan Arinaminpathy

Summary: This study analyzed the five most important regimen properties influencing the epidemiological impact of preventive tuberculosis treatment regimens, finding that efficacy is the most important predictor, with ease-of-adherence playing a significant secondary role. These results are consistent across different country settings and provide guidance for the further development of future treatment regimens.

BMC MEDICINE (2022)

Article Infectious Diseases

WHO target product profiles for TB preventive treatment

S. Den Boon, C. Lienhardt, M. Zignol, K. Schwartzman, N. Arinaminpathy, J. R. Campbell, P. Nahid, M. Penazzato, D. Menzies, J. F. Vesga, O. Oxlade, G. Churchyard, C. S. Merle, T. Kasaeva, D. Falzon

Summary: The WHO has developed target product profiles to guide the development of new tuberculosis treatment regimens. A technical consultation group identified attributes with the greatest potential impact for patients and populations, categorizing them as priority or desirable. The study identified nine priority attributes and four desirable attributes.

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2022)

Article Cell Biology

Interactions between nuclear and mitochondrial SNPs and Parkinson's disease risk

Sarah J. Pickett, Dasha Deen, Angela Pyle, Mauro Santibanez-Koref, Gavin Hudson

Summary: Interactions between nuclear and mitochondrial genomes play a critical role in the function of eukaryotic cells. A study investigating the frequencies of combinations of nuclear and mitochondrial SNP alleles in healthy individuals and Parkinson's disease patients identified some combinations that significantly affect the risk of the disease. These findings provide new insights into the impact of genetic background on disease susceptibility.

MITOCHONDRION (2022)

Article Biochemistry & Molecular Biology

Dynamics of the most common pathogenic mtDNA variant m.3243A > G demonstrate frequency-dependency in blood and positive selection in the germline

Melissa Franco, Sarah J. Pickett, Zoe Fleischmann, Mark Khrapko, Auden Cote-L'Heureux, Dylan Aidlen, David Stein, Natasha Markuzon, Konstantin Popadin, Maxim Braverman, Dori C. Woods, Jonathan L. Tilly, Doug M. Turnbull, Konstantin Khrapko

Summary: The A-to-G point mutation at position 3243 in the human mitochondrial genome (m.3243A > G) is the most common pathogenic mtDNA variant responsible for disease in humans. It is widely accepted that m.3243A > G levels decrease with age in blood, and a 2% annual decline correction is often applied. However, recent data suggest that the dynamics of m.3243A > G are more complex and depend on the mutation level in blood in a biphasic way. This biphasic approach can greatly improve the accuracy of modeling changes in mtDNA mutation frequencies.

HUMAN MOLECULAR GENETICS (2022)

Article Medicine, General & Internal

Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness

Ntwali Placide Nsengiyumva, Jonathon R. Campbell, Olivia Oxlade, Juan F. Vesga, Christian Lienhardt, Anete Trajman, Dennis Falzon, Saskia Den Boon, Nimalan Arinaminpathy, Kevin Schwartzman

Summary: This study analyzed the cost-effectiveness of scaling up tuberculosis preventive treatment regimens in Brazil and South Africa. The results showed that expanding the use of these regimens would significantly improve the effectiveness of tuberculosis prevention and treatment and would be cost-effective or cost-saving.

PLOS MEDICINE (2022)

Review Public, Environmental & Occupational Health

Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis

Leonardo Martinez, Olivia Cords, Qiao Liu, Carlos Acuna-Villaorduna, Maryline Bonnet, Greg J. Fox, Anna Cristina C. Carvalho, Pei-Chun Chan, Julio Croda, Philip C. Hill, Elisa Lopez-Varela, Simon Donkor, Katherine Fielding, Stephen M. Graham, Marcos A. Espinal, Beate Kampmann, Arthur Reingold, Helena Huerga, Julian A. Villalba, Louis Grandjean, Giovanni Sotgiu, Uzochukwu Egere, Sarman Singh, Limei Zhu, Christian Lienhardt, Justin T. Denholm, James A. Seddon, Christopher C. Whalen, Alberto L. Garcia-Basteiro, Rina Triasih, Cheng Chen, Jitendra Singh, Li-Min Huang, Surendra Sharma, Djohar Hannoun, Helena Del Corral, Anna M. Mandalakas, LaShaunda L. Malone, Du-Lin Ling, Afranio Kritski, Catherine M. Stein, Richa Vashishtha, Fadila Boulahbal, Chi-Tai Fang, W. Henry Boom, Eduardo Martins Netto, Antonio Carlos Lemos, Anneke C. Hesseling, Alexander Kay, Edward C. Jones-Lopez, C. Robert Horsburgh, Christoph Lange, Jason R. Andrews

Summary: This study aimed to investigate the age-specific impact of infant BCG vaccination on tuberculosis development and mortality. Through a systematic review and meta-analysis, the effectiveness of BCG vaccination was found to be significant in preventing tuberculosis in children younger than 5 years, but ineffective in adolescents and adults.

LANCET GLOBAL HEALTH (2022)

Article Immunology

Antimicrobial Resistance in Africa-How to Relieve the Burden on Family Farmers

Christian Ducrot, Alexandre Hobeika, Christian Lienhardt, Barbara Wieland, Charlotte Dehays, Alexis Delabouglise, Marion Bordier, Flavie Goutard, Ekta Patel, Muriel Figuie, Marisa Peyre, Arshnee Moodley, Francois Roger

Summary: Although Africa has the lowest antimicrobial usage in animals globally, there is a high prevalence of antimicrobial resistance in foodborne pathogens from animals. Farmers lack knowledge and misuse antimicrobials, posing a serious public health threat. Policy interventions should be tailored to address the challenges faced by family farmers in Africa and provide innovative measures to tackle antimicrobial resistance.

EMERGING INFECTIOUS DISEASES (2021)

No Data Available